Phase III

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.

Zealand Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon

Lead Product(s): Dasiglucagon

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycemia after meals in individuals who have undergone bariatric surgery.

Diurnal Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

Lead Product(s): Hydrocortisone

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eton Pharmaceuticals

Deal Size: $7.5 million Upfront Cash: $3.5 million

Deal Type: Licensing Agreement March 27, 2020

Details:

The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.

Provention Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes

Lead Product(s): Teplizumab

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

Details:

PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis

Oramed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

Lead Product(s): Exenatide

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: National Securities Corporation

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 27, 2020

Details:

The Company intends to use the net proceeds of the offering for its anticipated Phase 3 clinical trial in ORMD-0801 and for other clinical trials and R&D activities.

Lipocine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission

Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2020

Details:

The FDA requested that the information generated by the reanalysis be submitted as part of an NDA resubmission with a six-month Prescription Drug User Fee Act clock.

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Resverlogix Receives FDA Breakthrough Therapy for Apabetalone

Lead Product(s): Apabetalone

Therapeutic Area: Endocrinology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.

Find

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Product Type

Companies

Resverlogix Corp

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Zealand Pharma

Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon

Diurnal Group

Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

Provention Bio

Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

Lipocine

Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission

Resverlogix Corp

Resverlogix Receives FDA Breakthrough Therapy for Apabetalone